SCHEDULE 13G/A
Statement of Beneficial Ownership
Silence Therapeutics plc Filed Acc 0002005369-26-000060
Stakes reported in this filing
| Reporting person | Shares | Of the class |
|---|---|---|
| Raymond Debbane | 8,663,601 | 4.6% |
| Invus Public Equities, L.P. | 7,591,233 | 4.1% |
| Invus Public Equities Advisors, LLC | 7,591,233 | 4.1% |
| Invus Global Management, LLC | 7,591,233 | 4.1% |
| Siren, L.L.C. | 7,591,233 | 4.1% |
| Avicenna Life Sci Master Fund LP | 1,072,368 | 0.6% |
| Avicenna Life Sci Master GP LLC | 1,072,368 | 0.6% |
| Ulys, L.L.C. | 1,072,368 | 0.6% |
Members of a group can each report the same shares, so these rows overlap and don't add up.
Stake history · largest stake in each 13D and 13G
- 2026-11-16 SCHEDULE 13G/A · TCG Crossover GP I, LLC 3.9%
- 2026-11-12 SCHEDULE 13G/A · Raymond Debbane 4.6%
- 2026-11-05 SCHEDULE 13G · FMR LLC 7.1%
- 2026-10-13 SCHEDULE 13G/A · Tetragon Financial Group Limited 5.3%
- 2026-10-13 SCHEDULE 13G · Tetragon Financial Group Limited 5.2%
- 2026-08-13 SCHEDULE 13G/A · Raymond Debbane 7.0%
- 2026-08-13 SCHEDULE 13D/A · Richard Griffiths 7.97%
Loading xslSCHEDULE_13G_X02/primary_doc.xml…